Advertisement

Turning Point Therapeutics Licenses Its Lung Cancer Drug in China

Turning Point Therapeutics Licenses Its Lung Cancer Drug in China

Zai Labs will pay up to $176 million for the rights to sell repotrectinib in the Greater China market.